This disclosure provides particles that are suitable for remotely-triggered therapy for cancer and microbial infection. In an embodiment, this disclosure provides a particle heater comprising a carrier admixed with a material that interacts with an exogenous source; wherein the material absorbs and converts the energy from the exogenous source into heat, then the heat travels outside the particle heater to induce localized hyperthermia at a temperature sufficient to selectively kill unwanted cells, and further wherein the particle heater structure is constructed such that it passes the Extractable Cytotoxicity Test.

Reagents and methods to cloak and uncloak RNA polymers and applications thereof are provided. Photocloaking molecules are used to label RNA polymers. Radiant energy is used to remove photoreleaseable protecting adducts and revert a RNA polymer to its native form.

A nanocomposite includes an oxygen vacancy-containing BiOX particle and a coating, where the coating is a biocompatible material. Under near-infrared (NIR) irradiation, the nanocomposite has a photothermal conversion efficiency of greater than or equal to 10%. Under NIR irradiation, the nanocomposite degrades 1,3-diphenylisobenzofuran (DPBF) at a rate of higher than or equal to 0.1 mmol/h. BiOX may be BiOF, BiOCl, BiOBr, BiOI, or BiOAt. A preparation method and a use of the nanocomposite are further provided. The nanocomposite is a bismuth oxyhalide nanomaterial with different numbers of oxygen vacancies and can be used for the photothermal therapy (PTT) of a tumor and for the integrated tumor diagnosis and treatment. The nanocomposite leads to an excellent therapeutic effect under the guidance of multi-modality imaging, and has excellent computed tomography (CT) imaging and photoacoustic imaging (PAI) performance.

The present invention concerns amphiphilic copolymers that may be photo- or redox-cleavable and that may assemble into polymersomes. It also concerns their process of preparation and their use as ding carriers.

The present disclosure provides novel methods of maturing an AVF at the time of fistula creation comprising administering to an AVF a composition comprising at least one active agent chosen from a Compound of Formula (I) and pharmaceutically acceptable salts thereof and illuminating the at least one active agent on said AVF with visible light, such as, for example, 450 nm light.

Disclosed herein is a controlled drug release system of photoresponsive nanocarriers. Also provided are methods of making the nanocarriers. Also provided are method of using the nanocarriers for the treatment of diseases.

Near-infrared activatable fluorescent small molecules for the photodynamic treatment of cancer are provided. Methods of treatment include contacting a plurality of cells of the cancer with a near-infrared activatable fluorescent small molecule and directing a near-IR light to the molecule for an amount of time sufficient to induce release of the active platinum species and a reactive oxygen species.

In one aspect, compositions are described herein. A composition described herein comprises a nanoparticle, a therapeutic species, and a linker joining the nanoparticle to the therapeutic species. The linker joining the nanoparticle to the therapeutic species comprises a Diels-Alder cyclo-addition reaction product. Additionally, in some embodiments, the nanoparticle is a magnetic nanoparticle.

Methods for intravesical administration of a therapeutic agent including application of a photoactive nanogel to the mucosal surfaces of the bladder and/or intravesical application of cell-penetrating peptides. Photoactive nanogels may be aggregated by exposure to ultraviolet light, either in vitro or in vivo, to provide controlled or extended release of a therapeutic agent, such as an antibiotic.

The present invention pertains to an inventive release mechanism for extracellular vesicle (EV)-mediated intracellular and intramembrane delivery of therapeutic polypeptides. More specifically, the invention relates to EVs comprising polypeptide constructs which comprise a therapeutic polypeptide releasably attached to an exosomal polypeptide. Furthermore, the present invention pertains to manufacturing methods, pharmaceutical compositions, medical uses and applications, and various other embodiments related to the inventive EVs.